Abstract-Progressive cardiac remodeling is characterized by subsequent chamber hypertrophy, enlargement, and pump dysfunction. It is also associated with increased cardiac fibrosis and matrix turnover. Interestingly, peroxisome proliferator-activated receptor (PPAR) ␣ activators reduce cardiac hypertrophy, inflammation, and fibrosis. Little is known about the role of fenofibrates in mediating PPAR␣-independent effects in response to chronic pressure overload (PO). Wild-type and PPAR␣-deficient mice were subjected to chronic PO caused by ascending aortic constriction to test the role of fenofibrates in chronic, progressive cardiac remodeling by a PPAR␣-independent mechanism. Mice were randomized to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after ascending aortic constriction. In the presence of PPAR␣, wild-type chronic PO mice, treated with fenofibrate, had improved cardiac remodeling. However, PO PPAR␣-deficient mice treated with fenofibrate had increased mortality, significantly adverse left ventricular end diastolic (3.4Ϯ0.1 versus 4.2Ϯ0.1 mm) and end systolic (1.5Ϯ0.2 versus 2.5Ϯ0.2 mm) dimensions, and fractional shortening (57Ϯ3% versus 40Ϯ3%). Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2 in PO PPAR␣-deficient mice. Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation. Thus, fenofibrate improved cardiac remodeling in chronic PO mice. However, in PPAR␣-deficient mice, this chronic PO was exacerbated and associated with increased myocardial fibrosis and altered matrix remodeling. In the absence of PPAR␣, fenofibrates exerts deleterious, pleiotropic myocardial actions. This is an important observation, because PPAR␣ agonists are considered possible inhibitory regulators of cardiac remodeling in the remodeled heart. (Hypertension. 2007; 49:1084-1094.)
M
yocardial remodeling caused by chronic hemodynamic overload is characterized by increased myocardial hypertrophy, which, although initially compensatory, is an unfavorable component of cardiac remodeling when it becomes progressive. Progressive left ventricular (LV) remodeling is characterized by subsequent chamber enlargement and pump dysfunction. These alterations occur together with increased expression of inflammatory cytokines, 1 a shift from myocardial fatty acid oxidation to glucose use, 2 constant myocardial extracellular matrix turnover, 3 and matrix metalloproteinase (MMP) activation. 4 Aldosterone plays a key role in mediating adverse LV remodeling with pressure overload (PO). 5 It increases myocardial fibrosis that is independent of tissue hypertrophy and arterial pressure. 6, 7 Some of these effects are mediated directly by aldosterone, inducing MMP-2 and MMP-9 activities in cardiac myocytes. The mechanism partially involves activation of the MAP kinase kinase/extracellular signal-regulated kinase (ERK)1/2 pathway. 8 The benefits of targeted therapies to ameliorate progressive cardiac remodeling remain to be determined. In particular, the peroxisome proliferator-activated receptor (PPAR) family and their target genes appear to contribute in regulating lipid and glucose homeostasis and are implicated as regulators of inflammation and atherosclerosis. 9 Three ligand-activated transcription factors have been identified: PPAR␥, PPAR␤/␦ and PPAR␣. PPAR␥ is predominantly expressed in adipose tissue and regulates metabolism. PPAR␤/␦ is ubiquitously expressed 9 and regulates fatty acid oxidation genes. 9 In addition, PPAR␤/␦ activators exert anti-inflammatory and antihypertrophic effects in cardiomyocytes. 10 In contrast, PPAR␣ is abundant in tissues with high rates of mitochondrial fatty acid oxidation, (ie, heart, liver, and kidney) and regulates genes involved in cellular lipid catabolism. PPAR␣, the main isoform in the adult heart, 11 is downregulated in PO hypertrophy, 12 and its dysregulation is associated with cardiac dysfunction. 13 Conversely, PPAR␣ ligands reduce cardiac hypertrophy and inflammation 14, 15 and, in acute PO, attenuate cardiac fibrosis. 9 Finally, mice lacking PPAR␣ are reportedly resistant to pleiotropic actions of PPAR␣ ligands. 16 Fibrates are predominantly PPAR␣ but are also PPAR␤/␦ activators. 17 Fenofibrates are used clinically for dyslipidemia and hypertriglyceridemia, and it is through the activation of PPAR␣ that lipids are lowered. Likewise, fibrates have been considered as possible therapeutic agents for the treatment of cardiac hypertrophy 18 and failure. Independent of their lipidlowering actions, fenofibrates, as PPAR␣ agonists, may act as negative regulators of proinflammatory genes by antagonizing the activity of inflammatory transcription factors (eg, nuclear factor B 19,20 and activator protein-1 21 ), thus decreasing myocardial inflammation. 22 Likewise, inhibiting chronic inflammation in the remodeled myocardium is associated with a reduction in fibrosis. 9, 15, 23 In the present study, we tested the hypothesis that fenofibrate exerts beneficial effects on chronic, progressive cardiac remodeling and hypertrophy by PPAR␣-independent actions. The present studies were aimed at determining the role of fenofibrate in the pathogenesis of cardiac remodeling using both in vivo (wild-type and PPAR␣-deficient mice) and in vitro studies (cultured adult rat cardiomyocytes).
Methods

Animals
There were 2 groups of mice. Group A wild-type (WT) FVB mice were purchased from Charles River Laboratories (Wilmington, Mass) and group B PPAR␣-deficient mice (129S4/SvJaePpara tm1Gonz /J) were purchased from Jackson Laboratories (Bar Harbor, Maine). Study protocols were approved by the institutional animal care and use committee at Boston University.
Surgery
Both groups of mice underwent ascending aortic constriction (AAC) surgery as described previously. 5 Briefly, 12-to 14-week-old mice were anesthetized with pentobarbital (15 mg/kg IP injection) and then ventilated on a Harvard rodent respirator (model 683). Aortic constriction was performed by AAC with a 7-0 silk suture around a 27-gauge needle via an anterolateral thoracotomy. This technique provided a minimal variability of the trans-constriction pressure gradients in mice. 24 Sham-operated mice underwent a similar procedure without AAC.
Treatment
In group A, 32 mice (10 sham-operated and 22 banded) and, in group, B 50 mice (10 sham and 40 banded) were studied. Mice were randomly assigned to regular chow or chow-containing fenofibrate (100 mg/kg of body weight per day) for 1 week before and 8 weeks after surgery. A similar dose of fenofibrate was used by others [25] [26] [27] and shown to be nontoxic. Echocardiogram, blood pressure (BP), histology, and cardiac protein analyses were performed 8 weeks after surgeries.
Echocardiography and BP Measurement
Transthoracic echocardiography was performed in conscious mice before surgery (baseline) and 2, 4, and 8 weeks after surgery. Echocardiography was performed as described previously 5, 24 using an Acuson Sequoia C-256 echocardiograph machine and a 15-MHz probe. Tail cuff systolic BP and heart rate (HR) were measured at 8 weeks post-AAC, in group B, using a noninvasive tail cuff system (BP-2000, VisiTech) as described previously. 5, 28, 29 
Organ Weight
Mice were euthanized 8 weeks postoperatively. The body weight, LV heart weight, and wet and dry lung weights were determined. The wet/dry ratio was taken as an indicator of pulmonary congestion and clinical heart failure. 30 
Fibrosis
To measure fibrosis, trichrome-stained sections (5 m) were visualized by light microscopy, and the entire section was quantified using Bioquant Image analysis software.
Western Blot Analysis
Hearts from PPAR␣-deficient mice were removed and snap frozen in liquid nitrogen. The tissue was homogenized in cold lysis buffer (10ϫ cell lysis buffer, Cell Signaling) with the addition of 1 mmol/L of phenylmethylsulfonyl fluoride, 1 mmol/L of sodium orthovanadate, and 1 g/mL of aprotinin. The Bradford method (Bio-Rad) was used to measure protein concentration. SDS-PAGE was performed under reducing conditions on both 10% and 12% separation gels with a 4% stacking gel (Cambrex). Proteins were transferred to ImmunBlot polyvinylidene fluoride membrane (Bio-Rad). Blots were incubated with primary antibodies to the PPAR␥ (Santa Cruz Biotechnology Inc), PPAR␤/␦, MMP-9, tissue inhibitor of MMP (TIMP)-1, MMP-2, and TIMP-2 (Chemicon) for 18 to 20 hours at 4°C. Blots were then incubated in horseradish peroxidase-conjugated secondary antibody, and the signal was detected by SuperSignal West chemiluminescence (Pierce). All of the blots were normalized with Coomassie Brilliant Blue staining of the gels (Sigma Aldrich).
Isolation of Adult Rat Ventricular Myocytes
As described previously, 8 adult rat ventricular myocytes (ARVMs; 90% to 95% purity) were isolated from the hearts of adult SpragueDawley rats, plated at a nonconfluent density of 30 to 50 cells/mm 2 on plastic culture dishes (Fisher) precoated with laminin (1 g/cm 2 , Invitrogen), and maintained in ACCT medium (DMEM; BSA, 2 mg/mL; L-carnitine, 2 mmol/L; creatinine, 5 mmol/L; taurine, 5 mmol/L; penicillin, 100 IU/mL; and streptomycin, 10 g/mL) for 16 hours before drug treatment.
Drug Treatments
Myocytes were treated with aldosterone (50 nM, Sigma) for 30 minutes for signaling and 24 hours for zymography. Fenofibrate (10 M and 100 M, Sigma) was added 30 minutes before aldosterone.
ERK Phosphorylation
As described previously, 8 ARVMs were collected in lysis buffer. Protein concentration was determined using Bradford assay (BioRad). Protein was probed with anti-phospho-ERK1/2 (1:1000, Cell Signaling) or anti-total-ERK1 (1:1000, Cell Signaling) antibodies. Chemiluminescence was quantified by densitometry (Molecular Analyst, Bio-Rad).
Assessment of MMP Activity
Using in-gel zymography as described previously, 31 briefly ARVMs were treated for 24 hours in 100-mm dishes in medium without albumin. Conditioned medium was concentrated, and protein was determined by the Bradford assay. 32, 33 MMP activity was measured by in-gel zymography with gelatin (type A from porcine skin, Sigma) as the substrate. Unstained, digested regions representing MMP activity were quantified using an imaging densitometer (GS700, Bio-Rad).
Statistical Analysis
All of the data are presented as meanϮSEM. Differences between mice were tested for statistical significance by the 2-tailed Student t test or a 2-fold ANOVA with Bonferroni correction. Survival data were calculated using the Kaplan-Meier survival analysis. Similarly, in in vitro studies, differences among conditions were determined by ANOVA followed by a paired t test with the Bonferroni correction for multiple comparisons. PϽ0.05 was considered statistically significant.
Results
In Vivo Studies
Fenofibrate Effects on LV Structure and Function in WT Mice
Total wall thickness was increased by 2 weeks (1.22Ϯ0.09 mm versus sham: 0.99Ϯ0.02 mm; PϽ0.01), persisted at 4 weeks post-AAC, and slightly increased further by 8 weeks ( Figure 1A ). In addition, AAC caused progressive dilation with increases in LV end diastolic dimension and LV end systolic dimension that were evident at 2 weeks (3.37Ϯ0.09 and 1.97Ϯ0.01 mm, respectively), present at 4 weeks, and increased further at 8 weeks ( Figure 1B and  1C) . Thus, post-AAC, LV dilation was associated with a progressive decline in fractional shortening (FS), which was evident by 2 weeks (42Ϯ2% versus sham: 60Ϯ2%; PϽ0.0001) and continued to decline significantly at 4 and 8 weeks ( Figure 1D ).
Fenofibrate treatment significantly inhibited the increase in total wall thickness. This was evident at 2 weeks post-AAC (0.83Ϯ0.01 mm versus untreated AAC; PϽ0.001) and persisted at 4 and 8 weeks post-AAC ( Figure 1A ). In concert, by 2 weeks post-AAC, fenofibrate significantly reduced the increases in LV end diastolic dimension and LV end systolic dimension (3.85Ϯ0.07 mm and 2.2Ϯ0.07 mm versus untreated AAC, respectively; PϽ0.001; Figure 1B and 1C). In doing so, fenofibrate prevented the decrease in the percentage of FS seen at 2 (data not shown), 4, and 8 weeks with AAC ( Figure 1D ).
Survival in PPAR␣-Deficient Mice
Mice that survived the perioperative period were included in the Kaplan-Meier analysis as illustrated ( Figure 2 ). Fenofibrate decreased survival in the AAC mice in comparison with the untreated AAC group (65% versus 30%; PϽ0.05). During the 8 weeks after surgery, there were no deaths in either sham-operated group.
BP and Cardiac Morphology in PPAR␣-Deficient Mice 8
Weeks Post-AAC Systolic BP was not affected by fenofibrate. There was a trend to decrease BP in AAC mice (P not significant). In addition, fenofibrate treatment did not affect BP in either sham or AAC mice (Table) . AAC decreased HR 8 weeks post-AAC but was no different between untreated AAC and AAC ϩ fenofibrate mice. Hypertrophy is seen in AAC as is evident by the increased LV heart weight/body weight ratio (Table) . However, hypertrophy was increased in AAC ϩ fenofibrate (PϽ0.05 versus untreated AAC). In addition, fenofibrate also increased pulmonary congestion in AAC mice as shown by the increased wet/dry lung ratio (Table) .
Fenofibrate Effects on LV Structure and Function in PPAR␣-Deficient Mice
Similar to the increased LV heart weight/body weight ratio (Table) , fenofibrate increased total wall thickness in AAC (PϽ0.05) by echocardiography ( Figure 3A) . Regardless of the treatment in PPAR␣-deficient mice, AAC increased both LV end diastolic dimension and LV end systolic dimension. These were significant at 4 weeks and were further increased at 8 weeks ( Figure 3B and 3C) . AAC ϩ fenofibrate hearts were more dilated ( Figure 3B and 3C ). In concert, LV FS was progressively decreased in all of the AAC PPAR␣-deficient mice that were significant at 4 weeks and further decreased at 8 weeks. However, fenofibrate exacerbated the decline in LV percentage of FS in AAC at both 4 and 8 weeks ( Figure 3D ).
Myocardial PPAR␥ and PPAR␤/␦ Expression in PPAR␣-Deficient Mice
In sham and AAC hearts, PPAR␥ protein expression was not detectable by Western blot analysis regardless of treatment (data not shown). Similarly, PPAR␤/␦ protein expression was determined by Western blot analysis. Fenofibrate-treated AAC hearts exhibited a Ͼ9-fold increase in PPAR␤/␦ expression compared with untreated AAC hearts and sham hearts (14.7Ϯ4.6 versus 1.6Ϯ0.7 versus 1.7Ϯ0.6 arbitrary units (AU), respectively; Figure 4A and 4B).
Myocardial MMP and TIMP Expression in PPAR␣-Deficient Mice
The balance between MMP and TIMP expression is partially responsible for changes in the extracellular matrix. At 8 weeks post-AAC, MMP-2 protein expression was increased 39Ϯ26% (PϽ0.01 versus sham mice). Fenofibrate increased MMP-2 expression by 51Ϯ20% post-AAC (PϽ0.01 versus shamϩfenofibrate). But, there was no difference between the untreated AAC and AAC ϩ fenofibrate groups. Similarly, TIMP-2 expression was increased post-AAC untreated (50Ϯ11%; PϽ0.01 versus sham) but not in AAC ϩ fenofibrate (22Ϯ16%; P not significant versus shamϩfenofibrate; Figure  5A through 5C). Thus, the resulting MMP-2/TIMP-2 ratio, an index of net MMP activation, in PPAR␣-deficient mice was increased in AAC ϩ fenofibrate and unchanged in untreated-AAC hearts (6.9Ϯ1.0 versus 5.0Ϯ0.4; PϽ0.05; Figure 5G ). MMP-9 expression was not affected by AAC and fenofibrate treatment. TIMP-1 expression, its inhibitor, was increased post-AAC compared with untreated sham (11.4Ϯ4.3 versus 4.7Ϯ0.5 AU) and further increased in AAC ϩ fenofibrate hearts (22.8Ϯ1.9 AU). Thus, the ensuing MMP-9/ TIMP-1 ratio was significantly decreased (Ϸ2.5 fold) in AAC ϩ fenofibrate versus untreated AAC (1.0Ϯ0.1 versus 2.7Ϯ0.8; PϽ0.05; Figure 5D through 5G). 
Characteristics of PPAR␣-Deficient
Myocardial Fibrosis in PPAR␣-Deficient Mice
Examination of cross-sections taken from the LV showed positive trichrome staining indicative of fibrosis. Fibrosis was increased 69% in AAC ϩ fenofibrate hearts compared with untreated AAC hearts ( Figure 6A and 6B).
In Vitro Studies
Fenofibrates Induces ERK Phosphorylation in Culture in Aldosterone-Treated ARVMs We showed previously in ARVMs that aldosterone directly induces MMP-2 and MMP-9 activities. The mechanism partially involves activation of the MEK/ERK1/2 pathway. 8 We, thus, sought to explore the role of fenofibrate in aldosterone-mediated MMP expression in ARVMs. By Western blotting, treatment with aldosterone (50 nM) and fenofibrate (10 mol/L) for 30 minutes increased phospho-ERK1/2 by 55Ϯ11% and 32Ϯ6%, respectively. ERK1/2 phosphorylation tended to increase further when aldosterone was pretreated with fenofibrate (10 mol/L; P not significant versus aldosterone alone). Fenofibrate (100 mol/L) for 30 minutes also increased phospho-ERK1/2, but the addition of aldosterone inhibited the increase in phospho-ERK1/2 by 44% ( Figure 7A and 7B).
Fenofibrate Inhibits Aldosterone-Induced Increases in MMP Activity in ARVMs
In-gel zymography of conditioned medium from ARVM, treated with aldosterone (50 nM) for 24 hours, significantly increased MMP-2 (81Ϯ36%) and MMP-9 (32Ϯ5%) activities versus control ( Figure 7C through 7E) . Pretreatment with fenofibrate at 10 mol/L and 100 mol/L significantly abolished the increase in MMP-2 activity ( Figure 7D ) seen with aldosterone-treatment. Similarly, the aldosterone-induced increase in MMP-9 gelatinase activity was also significantly inhibited by both doses of fenofibrate (10 mol/L and 100 mol/L; Figure 7E ).
Discussion
In this study, fenofibrate ameliorated progressive LV dilation and systolic failure seen with AAC in chronic PO WT mice. These improved effects seen with fenofibrate are because of activation of the PPAR␣ ligand. In contrast, in a PPAR␣-independent manner, fenofibrate exacerbated LV dilation, systolic failure, fibrosis, and decreased survival in chronic PO PPAR␣-deficient mice. These PPAR␣-independent effects were associated with impaired matrix turnover as shown by the increased MMP-2/TIMP-2 ratio. There was also increased myocardial PPAR␤/␦ expression in fenofibrate-treated PO PPAR␣-deficient mice. The beneficial effects of fenofibrate, via activation of the PPAR␣ ligand, inhibited aldosteroneinduced phospho-ERK1/2 and MMP activity in cultured ARVM.
PPAR␣-deficient mice are reportedly refractory to pleiotropic responses induced by PPAR␣ ligands. 16 Moreover, cardioprotective effects of PPAR␣ activation during ischemia/reperfusion are abolished in PPAR␣-deficient mice. 34 Similarly, myocardial fibrosis appears in an age-dependent manner in PPAR␣-deficient mice. 35 We did not see evidence of cardiac fibrosis in sham PPAR␣-deficient mice, and this may be because of the younger age of our mice by the end of the study. Similarly, unlike the findings of Loichot et al, 36 we do not see decreased cardiac function or HR at baseline compared with WT mice (Figures 1 and 3) . Loichot et al 36 sedated their mice for echocardiography, 37, 38 and, because anesthesia decreases HR, which correlates with depressed cardiac function and contractility, 39 this may explain their adverse findings.
Nonetheless, our study aims to address the role of fenofibrates in pathological remodeling. Our data suggest that PPAR␣-independent actions of fenofibrate increase fibrosis and matrix turnover and are partly responsible for the adverse effects seen in the chronic PO myocardium. In the absence of PPAR␣, fenofibrate exerted deleterious effects, which were associated with increased MMP-2 expression and a reduction in TIMP-2 expression. The myocardial MMP-2/TIMP-2 ratio, an index of net MMP activation, was increased in fenofibrate-treated PO PPAR␣-deficient mice, as was the fibrosis indicating increased matrix turnover, which may contribute to the LV hypertrophy seen. The increased LV hypertrophy seen with fenofibrate treatment in PPAR␣-deficient mice was not associated with elevated BP. Additionally, there was increased ANP expression (data not shown), a molecular marker of hypertrophy, in fenofibratetreated PO PPAR␣-deficient mice. Fenofibrate had no affect on sham PPAR␣-deficient mice, suggesting that these negative effects may be apparent only during conditions of "stress," for example, such as during renin-angiotensinaldosterone system activation with increased aldosterone or PO. 5, 8 The adverse effects (cardiac remodeling and fibrosis) of fenofibrate were not because of a lowering of tail-cuff BP (because there is no difference between treated or untreated PO PPAR␣-deficient mice). There was evidence of "clinical" heart failure in the mice, as demonstrated by a trend to decreased systolic BP in both of the AAC (PO) groups, the slight decrease in HR, and the increased pulmonary congestion (ie, wet/dry lung ratio).
Studies have demonstrated that MMP-2 and MMP-9 are augmented in dilated failing hearts [3] [4] [5] and involved in the development and progression of myocardial remodeling. 3 Similarly, MMP-2 and MMP-9 are increased during ischemia/reperfusion and are attenuated by PPAR␣ agonists. 34 Selective disruption of the MMP-2 gene ameliorated myocyte Fenofibrates induces ERK signaling in aldosterone-treated ARVMs. A, Treatment of ARVM with aldosterone (50 nM) and fenofibrate (10 mol/L) increased phospho-ERK1/2 by 55Ϯ11% and 32Ϯ6%, respectively (#PϽ0.01 vs control). Phospho-ERK1/2 tended to increase further when fenofibrate (10 mol/L) was added to the aldosterone (P not significant vs aldosterone). Fenofibrate (100 mol/L) for 30 minutes also increased phospho-ERK1/2 (*PϽ0.05 vs control), but the addition of aldosterone inhibited the increase in ERK1/2 phosphorylation by 44% (P not significant vs fenofibrate, 100 mol/L; §PϽ0.05 vs aldosterone). Data are normalized to total ERK. B, Representative Western blot of ERK signaling. Data are meanϮSEM. Fenofibrate abrogates aldosterone-stimulated MMP activity in ARVM. C, Representative gelatin zymogram of MMP activity in conditioned medium taken from untreated LV myocytes and those treated with 50 nM aldosterone (Aldo); 10 mol/L Fen; Fen (10 mol/L)/Aldo; 100 mol/L Fen; Fen (100 mol/L)/Aldo (10 5 total cells; nϭ6). MMP gelatinolytic activity was observed between 100 and 50 kDa, which is consistent with MMP-2 and MMP-9. MMP gelatinase activity is summarized in D and E. Fen indicates fenofibrate. D, MMP-2 gelatinase activity was localized to Ϸ70 kDa. MMP-2 gelatinase activity in LV myocyte-conditioned medium was increased by 81Ϯ36% after treatment with aldosterone (*PϽ0.05 vs control). Fenofibrate at both 10 mol/L and 100 mol/L doses inhibited the increase in MMP-2 activity by Ϫ88Ϯ14% and Ϫ120Ϯ6%, respectively, seen with aldosterone ( ‡PϽ0.01 vs aldosterone). E, MMP-9 gelatinase activity was localized to Ϸ90 kDa. MMP-9 gelatinase activity was increased 32Ϯ5% after treatment with aldosterone (#PϽ0.01 vs control). Fenofibrate at both 10 mol/L and 100 mol/L doses inhibited the increase in MMP-9 activity 38Ϯ3% and 64Ϯ12%, respectively, seen with aldosterone ( §PϽ0.01 vs aldosterone). Data are meanϮSEM.
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hypertrophy and interstitial fibrosis in PO mice. 40 Thus, our data support the evidence that MMP-2 is involved in mediating PO-induced ventricular hypertrophy. Although MMP-2 was increased in untreated PO PPAR␣-deficient mice, it was further increased with fenofibrate treatment. TIMP-2 was increased in untreated AAC, but the expression of this inhibitor of MMP-2, in fenofibrate-treated AAC, was not as distinct. Although MMP-9 expression was not increased in fenofibrate-treated AAC, 21 its inhibitor TIMP-1 possibly compensated for the lack of TIMP-2 expression by increased TIMP-1 expression. Similarly, fenofibrate may increase TIMP-1 expression to increase MMP-2 expression (because TIMPs participate in the process of MMP activation). 41 Although we could not test for a cause or an effect in this in vivo model, the lack of an increase in the MMP-9/TIMP-1 ratio in AAC ϩ fenofibrate mice may contribute to the adverse effects of fenofibrate on cardiac function and survival. Thus, PPAR␣ may have a protective role in preventing fenofibrate-induced exacerbation of hypertrophy in this model by its effect on MMP and TIMP interactions. Fenofibrate is a weak activator of PPAR␤/␦ and in other cell systems activates other pathways that are not PPAR dependent, such as non-receptor-mediated (nongenomic) effects. 42 There are other possible hypothesizes for an unfavorable outcome in fenofibrate-treated PO PPAR␣-deficient mice in addition to increasing fibrosis, mortality, and activating MMPs. These non-PPAR␣-mediated effects include proapoptosis by inhibiting Akt phosphorylation 43 and proapoptotic gene activation resulting in the progression to heart failure. 44 In addition, there may be a precedent for significant species variation in PPAR-mediated responses, 45 but they may also be related to the experimental model used to induce cardiac remodeling, for example, rats with myocardial infarction, 46 pigs with ischemia/reperfusion, 47 and humans with diabetes. 48, 49 We also measured other isoforms of PPAR ligands in this whole body deletion of PPAR␣. There was negligible myocardial expression of PPAR␥. Interestingly, myocardial expression of PPAR␤/␦ was significantly increased in fenofibrate-treated PO PPAR␣-deficient mice. The role of PPAR␤/␦ is unclear in cardiac remodeling. It has been suggested that PPAR␤/␦ agonists inhibit cardiac hypertrophy. 20 Our data do not demonstrate a cause and an effect; increased PPAR␤/␦ expression in fenofibrate-treated PO PPAR␣-deficient mice is associated with adverse cardiac remodeling and requires further investigation. It is more likely that the adverse effects of fenofibrates would be even more marked in the absence of PPAR␤/␦ upregulation. Thus, PPAR␤/␦ expression may merely be a marker of comparatively worse LV function and adverse remodeling. PPAR␤/␦ expression was measured in fenofibrate-treated WT PO mice with chronic remodeling, that is, in the presence of PPAR␣ ligands; there was no upregulation in PPAR␤/␦ expression (data not shown).
Similar to Dahl salt-sensitive rats 50 and deoxycorticosterone acetate-salt hypertensive rats, 9, 15, 23 fenofibrate, in our study, exerts beneficial effects on cardiac remodeling via PPAR␣ activation in WT mice. The beneficial effect seen in our study is a decrease in wall thickness, a reduction in ventricular dilation, and an improvement in FS. We have shown that inflammatory cytokines and reactive oxygen species regulate myocardial MMP, 8, 51 and we now demonstrate that fenofibrate regulates the extracellular matrix in cardiac remodeling. The benefits of fenofibrates (by inhibiting aldosterone-induced increases in MMP activity) in vitro are partly because of PPAR␣-dependent activation by fenofibrate, and there was no increased PPAR␤/␦ or PPAR␥ expression in ARVMs treated with fenofibrate (data not shown). The mechanisms of the improved chronic cardiac remodeling with fenofibrate (unrelated to their lipid-lowering actions) have been associated with effects on the vasculature, 22 inhibition of proinflammatory 19 and redox-sensitive 50 transcription factors, and on cell infiltration 52 and MMP-9 21 inhibition.
Perspectives
Fenofibrates are beneficial in progressive PO-induced cardiac remodeling, likely because of the presence of PPAR␣. Our study demonstrates, in cardiac remodeling, that the benefits of fenofibrate are partly because of aldosterone-stimulated inhibition of phospho-ERK and MMP. The adverse effects of fenofibrate (present only when PPAR␣ is absent) are because of activation of MMP, increased fibrosis, left ventricular hypertrophy, and increased mortality. These findings indicate that, with PPAR␣ deficiency, fenofibrates exert deleterious pleiotropic actions in the failing myocardium.
Interestingly, in human studies, several polymorphisms of the PPAR␣ locus have been described. 53 The V162 allele is associated with alterations in lipids and decreased cardiovascular events in diabetics. 49 The effect of PPAR␣ agonists with this allele is variable 53, 54 and requires further investigation. 49 Because current heart failure therapies are directed at the inhibition of neurohormonal pathways, these results may provide a basis for future strategies to prevent or reverse cardiac remodeling in PO hypertrophy. However, despite their positive effects on cardiac physiology in vivo, the therapeutic benefit for fibrates in human heart failure requires longer-term studies to monitor their effects on cardiac function. Moreover, closer observation may be necessary in humans undergoing chronic fibrate therapy. 48 
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